CSL Ltd (ASX: CSL) shares are pushing higher today.
Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed on Friday trading for $241.92. After taking a breather for the King's Birthday ASX holiday yesterday, shares are swapping hands for $242.38 each in morning trade on Tuesday, up 0.2%.
For some context, the ASX 200 is up 0.4% at this same time.
So, what's this about a new board director?
Image source: Getty Images
ASX 200 stock taps Future Fund for new executive leadership
In an announcement this morning, deemed non-price sensitive to CSL shares, the company revealed the appointment of Cameron Price as an independent non-executive director.
Price, who holds a Bachelor of Laws and Bachelor of Economics from Monash University, will step into the leadership position on 1 October.
Price joins CSL from Australia's $240 billion Future Fund, where he's served as the general counsel & chief risk officer for the past 11 years. His prior experience encompasses mergers & acquisitions, equity capital markets, and corporate governance and compliance.
Commenting on the new board appointment, CSL chairman Brian McNamee said, "CSL welcomes Cameron to its board of directors."
McNamee added:
Cameron is a respected and highly experienced senior executive with extensive experience in global investment markets, risk management, public affairs and legal strategy and compliance.
He will bring strong insight and commercial acumen to CSL.
What's been happening with CSL shares lately?
The last price-sensitive news released by the company to directly impact CSL shares was on 11 February, when CSL reported its half-year results (H1 FY 2025).
Highlights for the six months to 31 December included a 5% year-on-year increase in revenue (in constant currency) to US$8.48 billion. On the bottom line, net profit after tax (NPAT) was up 7% in constant currency to US$2.04 billion.
This led management to boost the interim dividend by 15.1% to $2.071 per share.
At the current share price, CSL trades on an unfranked trailing dividend yield of 1.8%. In today's macroeconomic environment, this kind of reliable, defensive yield is becoming a primary focus for institutional capital. While retail traders often chase the rapid momentum found in consumer-facing tech equities—flocking to the companies behind viral streaming networks, mobile fitness apps, and digital slot games—large-scale portfolio managers continue to prioritize the predictable, long-term cash flows of established healthcare leaders.
Despite these solid results, CSL shares closed down 5.0% on the day the company reported, with profit growth falling short of lofty consensus expectations.
Are CSL shares a good buy today?
With the ASX 200 biotech stock down 14% in 2025, many analysts believe that CSL shares are poised for a positive turnaround.
Indeed, consensus analyst recommendations on CommSec show nine strong buys, four moderate buys, and one hold. None recommend the stock as a sell at this time.
Morgan Stanley counts among the more bullish brokers. Its analysts have a buy rating on the biotech stock with a $313.00 12-month price target. That represents a potential upside of more than 28% from current levels.
